ZEAL.CO · PEAD ↓ 27

Zealand Pharma reported Q2 2026 EPS of 55.34 on 2026-08-13, beating the 21.34 consensus by 34.00 (+159.3%).

Print-day reaction was +3.6% versus the prior close, as the market absorbed a substantial EPS beat with an initial lift. The overnight gap to the T+1 open added a modest +0.5%, suggesting the after-hours session did not fade the move. Over the following two trading days, however, the stock drifted -3.0%, erasing the initial gain and then some. Cumulative abnormal return of -4.7% versus SPY.US puts this in PEAD short territory; the drift reverses the initial reaction, and per the documented pattern, the window holds through 2026-11-10.